​Kembara Xtra - Medicine - Babesiosis

​Kembara Xtra - Medicine - Babesiosis 
Basic description: Intraerythrocytic Babesia parasites cause this uncommon tick-borne hemolytic illness.
 Seldom noted outside of the United States
– Sporadic cases have been reported from: France, Italy, the former Soviet Union, the United Kingdom, Ireland, and Mexico.
Turkey, Italy, and China have all reported an increase in cases.
– Infections have been detected in a number of states in the US. Islands off the coast of Massachusetts (including Nantucket and Martha's Vineyard), New York (including Long Island, Shelter Island, and Fire Island), Connecticut, and Alaska are where the species is most endemic.
 Infections with no symptoms are frequent in these locations.
The incubation phase lasts between 5 and 33 days:
– Most patients can't specifically recall being exposed to ticks.
– The incubation period following transfusion of contaminated blood may last up to 9 weeks.

Systems impacted: cardiovascular, digestive, hemic/lymphatic/immunologic, musculoskeletal, neurological, pulmonary, renal/urologic, and urologic/renal
Child Safety Considerations
Rare reports of transplacental and neonatal transmission

Geriatric Considerations Patients >60 years of age have higher rates of morbidity and mortality Patients >70 years of age with medical comorbidities have higher rates of cases.


Babesiosis affects patients of all ages in terms of epidemiology. The majority of patients arrive in their 40s or 50s.
Coinfection with other tick-borne diseases is becoming more widely acknowledged.
Incidence
Prevalence is difficult to assess due to a lack of surveillance and asymptomatic infections. Cases reported to the Centers for Disease Control and Prevention (CDC) range from 911 in 2012 to 2,368 in 2017 before significantly declining to 2,101 in 2018.
There have been reports of transfusion-associated babesiosis and transplacental/perinatal transmission.
Seroconversion results show antibodies to Babesia microti in 7 out of 671 people (1%), including patients at high risk for illnesses spread by ticks.

PATHOPHYSIOLOGY AND ETIOLOGY
The majority of human illnesses are brought on by B. microti (in the United States), Babesia divergens, and Babesia bovis (in Europe). 
Babesia duncani appears to be more virulent than B. divergens. Case reports identify other species. They all have similar morphologic, antigenic, and genetic traits.
The main vectors are ixodid (hard-bodied) ticks, specifically Ixodes dammini (Ixodes scapularis: deer tick) and Ixodes ricinus.
The main reservoir is the white-footed deer mouse, and humans are infected when a tick in the nymphal stage of development feeds on their blood. During the bite, sporozoites are transported into red blood cells where they undergo binary fission to create merozoites (classic shape on blood smear). The host of last resort for B. microti is the human.

RISK FACTORS Include living in endemic regions, asplenium, and an immune-compromised state.


DURATIONAL PREVENTION
Avoid visiting endemic areas from May to September, when transmission is at its highest. Wear appropriate bug repellent when outside, especially in grassy or forested areas.
- 10-35% N,N-diethyl-meta-toluamide (DEET) offers sufficient skin defense.
Early tick removal—daily skin checks; acaricides, such as permethrin, offer impregnated clothing with even more protection.
Check pets for ticks and treat them for fleas and ticks.

CONDITIONS OFTEN Associated with
Co-infection, particularly in endemic areas, with Borrelia burgdorferi and B. microti. Co-infection rates could reach 27%.
Ehrlichia infection co-infection

DISEASE HISTORY
Before B. microti transmission happens, the tick must be attached for at least 24 hours.
Comorbidities (immunosuppression, chronic disease) History of travel or exposure Fever (68-89%), fatigue (78-79%), chills (39-68%), sweats (41-56%), headache (32-75%), myalgia (32-37%), anorexia (24-25%), cough (17-23%), arthralgias (17-32%), and nausea (9-22%). Case reports also list emotional lability, nausea, vomiting, and stomach pain as additional symptoms.

HIGH FEVER (UP TO 40°C [104°F]) DURING PHYSICAL EXAM
Hemodynamic instability (shock in critically unwell patients)
Mild if noticeable hepatomegaly and splenomegaly
Rash (rare; if present, take Lyme disease into consideration)
Headache, photophobia, stiffness in the neck and back, altered sensorium, and emotional lability are just a few of the symptoms of the central nervous system's involvement. Jaundice and black urine may also appear later in the course of the illness.

DIFFERENTIAL DIAGNOSIS HIV, Epstein-Barr virus, leishmaniasis, malaria, increased liver enzymes, low platelet syndrome (in pregnancy), bacterial sepsis, hepatitis, ehrlichiosis, Rocky Mountain spotted fever, leishmaniasis, leishmaniasis, and leishmaniasis

DETECTION & INTERPRETATION OF DIAGNOSIS
Initial examinations (lab, imaging)
A high clinical suspicion index is necessary for diagnosis.
The presence of mild to severe hemolytic anemia, a normal or slightly depressed leukocyte count, an elevated lactate dehydrogenase or transaminase level, an elevated blood urea nitrogen and creatinine level, proteinuria, and hemoglobinuria are examples of nonspecific laboratory clues.

● Using a blood smear, a definitive diagnosis is achieved.
– Intraerythrocytic parasites can be seen in a peripheral blood smear that has been Wright- or Giemsa-stained.
– Tetrads of merozoites that divide "cross-like" (Maltese cross) are pathognomonic.
– Serial blood smears could be necessary (early-stage parasite load is modest).
– Plasmodium falciparum on peripheral smear can be mistaken for it.
IgM serologies by indirect immunofluorescent antibody testing (IFAT) for B. microti antigen are used if blood smears are negative but suspicion is still there.
– By lab, positive titer findings can differ. A B. microti infection is consistent with titers of >1:64 or a 4-fold increase from baseline. In cases of acute infection, titers may exceed 1:1,024. Titers frequently rise 8 to 12 months after being low for years.
– Seroprevalence ranges from 0.5 to 16% in New England.
In acute instances, the polymerase chain reaction (PCR) is more sensitive and similarly specific for detecting B. microti. PCR can also be used to track the development of diseases. Modern real-time PCR assays are getting close to 100% in terms of sensitivity and specificity.
Inoculating laboratory animals with patient blood can reveal B. microti organisms in the animal's blood within 2 to 4 weeks if lab tests are equivocal and infection is highly suspected.
Tests in the Future & Special Considerations
Treatment is guided by monitoring intraerythrocytic parasitemia.
Other/Diagnostic Procedures
based on blood test results, family history, and epidemiological data

GENERAL TREATMENT MEASURES
Consider adding doxycycline 100 mg BID PO to treat a coinfection in locations where ehrlichiosis and Lyme disease are common until serologic testing is finished.
Drug resistance has developed in people with severe immunosuppression.
If parasitemia persists for more than three months, take into account treating asymptomatic individuals; otherwise, avoid treating in the absence of symptoms.

First Line: MEDICATION
B. microti infection that is mild to moderate is treated with atovaquone 750 mg PO (with a fatty meal) BID for 7 to 10 days, as well as azithromycin 500 mg PO BID on day 1 and 250 mg/day after that. Pediatrics: 10 mg/kg (maximum 500 mg) of azithromycin on day 1 and 5 mg/kg (maximum 250 mg) on day 2; atovaquone 20 mg/kg (maximum 750 mg) BID. The same dosage is advised for severe B. microti infections, although azithromycin can be administered intravenously. A different kind of treatment involves administering 650 mg of oral quinine TID or QID together with 300 to 600 mg of IV clindamycin QID for 7 to 10 days.
pediatrics: quinine 8 mg/kg (maximum 650 mg) TID and clindamycin 7 to 10 mg/kg (maximum 600 mg) TID or QID.
Babesiosis that is persistent or relapsing requires treatment for six weeks, including two weeks after Babesia is no longer visible on a blood test.

Second Line The most often used treatment is a combination of quinine sulfate 650 mg PO TID and clindamycin 600 mg PO TID or 1.2 g parenterally BID for 7 to 10 days.
Pediatric: 8 mg/kg of quinine (maximum 650 mg) PO every 6 to 8 hours for 7 to 10 days; 7 to 10 mg/kg of clindamycin (maximum 600 mg) PO every 6 to 8 hours for 7 to 10 days. For serious infections, some physicians favor this treatment plan.
There have been evaluations of additional medications like tetracycline, primaquine, sulfadiazine (Microsulfon), and sulfadoxine/pyrimethamine (Fansidar). Results can vary. Pentamidine (Pentam) has a mediocre efficacy in reducing symptoms and parasitemia.

ALERT
Diarrhea linked with Clostridium difficile may result from using clindamycin.

QUESTIONS FOR REFERENCE
Severe illness: If a patient is exceedingly unwell (blood parasitemia > 10%, significant hemolysis, and asplenia), consider consulting with hematology and infectious disease specialists before administering an exchange transfusion.

CONSIDERATIONS FOR ADMISSION, THE INPATIENT, AND NURSING
For a few patients with severe babesiosis and organ deterioration, an exchange transfusion may be an option.

CONTINUING CARE AFTERCARE RECOMMENDATIONS
Silent babesiosis can last for months or even years if ignored.

The severity of the condition is correlated with alkaline phosphatase levels >125 U/L, white blood cell counts >5 109/L, a history of cardiac abnormalities, a history of splenectomy, the existence of a heart murmur, and parasitemia of 4% or higher.

patient observation

The degree of the condition determines the requirement for monitoring.
virulent infections Until clinical improvement and parasitemia is less than 5%, monitor hematocrit and levels. Mild to medium Within 48 hours, expect clinical improvement, and three months, full recovery.

COMPLICATIONS
Many continue to be asymptomatic.
Congestive heart failure (12%), disseminated intravascular coagulation (18%), acute respiratory distress syndrome (21%), renal failure (6%), coma/lethargy (9%), and death (9%) are complications in hospitalized patients.
Myocardial infarction and neutropenia are two more problems that have been noted.
Warm autoimmune hemolytic anemia in asplenic patients has been documented.

---